% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Bexte:277341,
      author       = {T. Bexte and L. M. Reindl and E. Ullrich$^*$},
      title        = {{N}on-viral technologies can pave the way for {CAR}-{NK}
                      cell therapy.},
      journal      = {Journal of leukocyte biology},
      volume       = {114},
      number       = {5},
      issn         = {0741-5400},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {DKFZ-2023-01349},
      pages        = {475-486},
      year         = {2023},
      note         = {2023 Oct 26;114(5):475-486},
      abstract     = {Natural killer (NK) cells are a promising platform for
                      cancer immunotherapy. NK cells have high intrinsic killing
                      capability, and the insertion of a chimeric antigen receptor
                      (CAR) can further enhance their anti-tumor potential. In
                      first human trials, CAR-NK cells demonstrated strong
                      clinical activity without therapy-induced side effects. The
                      applicability of NK cells as an 'off-the-shelf' product
                      makes them highly attractive for gene-engineered
                      cell-therapies. Traditionally, viral transduction has been
                      used for gene-editing; however, the use of viral vectors
                      remains a safety concern and is associated with high costs
                      and regulatory requirements. Here, we review the current
                      landscape of non-viral approaches for CAR-NK cell
                      generation, which include transfection of vector particles
                      and electroporation of mRNA and DNA vectors resulting in
                      transient gene-modification and CAR expression. In addition,
                      using non-viral transposon technologies, NK cells can be
                      stably modified ensuring long-lasting CAR expression.
                      Finally, we discuss CRISPR/Cas9 tools to edit key genes for
                      NK cell functionality.},
      subtyp        = {Review Article},
      keywords     = {CAR (Other) / CRISPR (Other) / electroporation (Other) /
                      mRNA (Other) / natural killer cell (Other) / non-viral
                      (Other) / transposon (Other)},
      cin          = {FM01},
      ddc          = {570},
      cid          = {I:(DE-He78)FM01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37403203},
      doi          = {10.1093/jleuko/qiad074},
      url          = {https://inrepo02.dkfz.de/record/277341},
}